HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van den Berg, J W K Articles by van der Bij, W Search for Related Content PubMed PubMed Citation Articles by van den Berg, J W K Articles by van der Bij, W

Thorax 1999;54:550-553 ( June )

Occasional review

New immunosuppressive drugs and lung transplantation: last or least?

J W K van den Berg, D S Postma, G H Koëter, W van der Bij

Department of Pulmonary Diseases and Lung Transplantation, University Hospital Groningen, P O Box 30001, 9700 RB Groningen, The Netherlands

Correspondence to: Dr J W K van den Berg.

Received 11 March 1998; Returned to authors 8 May 1998; Revised version received 7 December 1998; Accepted for publication 7 December 1998

The first 150 words of the full text of this article appear below.

	Introduction

Lung transplantation has become an accepted treatment modality for end stage lung disease.¹ Traditionally, immunosuppressive maintenance therapy consists of cyclosporin, azathioprine, and prednisolone in kidney and liver transplantation as well as in lung transplantation. Despite the use of these drugs, acute rejection occurs frequently, especially in the first weeks and months after lung transplantation. Although these periods are now almost never life threatening, they are associated with substantial morbidity. Prevalences of acute rejection ranging from 60% to 100% have been reported, depending on whether acute rejection is based on clinical or histological diagnosis.^2-4 The incidence of acute rejection is far higher after lung transplantation than after any other form of solid organ transplantation. This may be due to the fact that the donor lung contains a substantial amount of immunocompetent tissue and because the lungs are constantly exposed to environmental factors.⁵

Bronchiolitis obliterans syndrome (BOS) is the major cause of . . . [Full text of this article]

This article has been cited by other articles:

				E. Koletsis, A. Chatzimichalis, E. Apostolakis, K. Kokkinis, V. Fotopoulos, M. Melachrinou, M. Chorti, J. Crockett, E. Marinos, I. Bellenis, et al. In Situ Cooling in a Lung Hilar Clamping Model of Ischemia-Reperfusion Injury Experimental Biology and Medicine, September 1, 2006; 231(8): 1410 - 1420. [Abstract] [Full Text] [PDF]

				Y. Takehisa, S. Sakiyama, T. Uyama, M. Sumitomo, M. Tamaki, H. Hino, M. Takehisa, M. Liu, K. Kondo, and Y. Monden Progressive increase of CD4+/CD45RC- lymphocytes after allograft rat lung transplantation: A marker of acute rejection J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 675 - 683. [Abstract] [Full Text] [PDF]

				J. W. K. van den Berg, P. J. van Enckevort, E. M. TenVergert, D. S. Postma, W. van der Bij, and G. H. Koeter Bronchiolitis Obliterans Syndrome and Additional Costs of Lung Transplantation Chest, December 1, 2000; 118(6): 1648 - 1652. [Abstract] [Full Text] [PDF]